These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38417778)

  • 1. Familial hypercholesterolemia with special focus on Japan.
    Kobayashi J; Minamizuka T; Tada H; Yokote K
    Clin Chim Acta; 2024 Mar; 556():117847. PubMed ID: 38417778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
    Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
    Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
    Awan Z; Baass A; Genest J
    Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
    Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
    Page MM; Stefanutti C; Sniderman A; Watts GF
    Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene.
    Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
    Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P
    Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
    Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
    Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
    Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia.
    Lye SH; Chahil JK; Bagali P; Alex L; Vadivelu J; Ahmad WA; Chan SP; Thong MK; Zain SM; Mohamed R
    PLoS One; 2013; 8(4):e60729. PubMed ID: 23593297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic backgrounds and diagnosis of familial hypercholesterolemia.
    Rogozik J; Główczyńska R; Grabowski M
    Clin Genet; 2024 Jan; 105(1):3-12. PubMed ID: 37849044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study.
    Iannuzzo G; Buonaiuto A; Calcaterra I; Gentile M; Forte F; Tripaldella M; Di Taranto MD; Giacobbe C; Fortunato G; Rubba PO; Di Minno MND
    Nutr Metab Cardiovasc Dis; 2022 Mar; 32(3):684-691. PubMed ID: 34991937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
    Damgaard D; Jensen JM; Larsen ML; Soerensen VR; Jensen HK; Gregersen N; Jensen LG; Faergeman O
    Atherosclerosis; 2004 Dec; 177(2):415-22. PubMed ID: 15530918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of familial hypercholesterolemia.
    Brautbar A; Leary E; Rasmussen K; Wilson DP; Steiner RD; Virani S
    Curr Atheroscler Rep; 2015 Apr; 17(4):491. PubMed ID: 25712136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
    Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
    Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.